EYEN.Eyenovia, INC
10-Q: Eyenovia Reports Second Quarter 2024 Results, Reacquires Key Asset
Sentiment:
Quarterly Report
Eyenovia's Q2 2024 results show a net loss, increased R&D spending, and the reacquisition of rights to its MicroPine product.
Capital raiseThe company raised $5.0 million in gross proceeds from a registered direct offering on July 1, 2024.The company raised $0.8 million in gross proceeds from an at-the-market offering subsequent to June 30, 2024.The company's ability to continue as a going concern is dependent on raising additional capital.
Worse than expectedThe company's net loss was significantly higher compared to the same period last year.The company's cash position has deteriorated, leading to substantial doubt about its ability to continue as a going concern.The company's working capital deficit has increased.
Summary
- Eyenovia reported a net loss of $11.1 million for the three months ended June 30, 2024, and a net loss of $22.0 million for the six months ended June 30, 2024.
- The company's revenue for the three months ended June 30, 2024, was $22,625, and $27,618 for the six months ended June 30, 2024, primarily from sales of Mydcombi.
- Research and development expenses increased to $4.6 million for the three months and $9.0 million for the six months ended June 30, 2024, driven by increased clinical trial costs and Gen-2 device development.
- General and administrative expenses were $3.8 million for the three months and $7.4 million for the six months ended June 30, 2024, reflecting increased staffing and commercialization efforts.
- Eyenovia reacquired the rights to its MicroPine product from Bausch + Lomb, incurring a $2.9 million expense for the quarter and $4.9 million for the six months ended June 30, 2024.
- The company had a working capital deficit of $8.6 million and an accumulated deficit of $167.5 million as of June 30, 2024.
- Eyenovia raised $5.0 million in gross proceeds from a registered direct offering on July 1, 2024, and $0.8 million from an at-the-market offering subsequent to June 30, 2024.
Sentiment
Score: 4
Explanation: The document highlights significant financial losses and concerns about the company's ability to continue as a going concern. While there are positive developments such as the reacquisition of MicroPine and new collaborations, the overall financial situation and the need for further capital raises create a negative sentiment.
Positives
- Eyenovia successfully reacquired the rights to its MicroPine product, which could increase the value of the asset.
- The company has expanded its manufacturing capabilities and received FDA approval for its primary Mydcombi manufacturing facility.
- Eyenovia has begun commercialization of Mydcombi and expanded its sales team.
- The collaboration with Senju could lead to a new product for chronic dry eye disease.
- The company regained compliance with Nasdaq's minimum bid price requirement.
Negatives
- Eyenovia reported a significant net loss for both the three and six months ended June 30, 2024.
- The company has a working capital deficit and an accumulated deficit.
- There is substantial doubt about the company's ability to continue as a going concern.
- The company experienced a write-down of inventories to net realizable value of approximately $0.7 million for the six months ended June 30, 2024.
- The company incurred significant expenses related to the reacquisition of the MicroPine license.
Risks
- The company's ability to continue as a going concern is dependent on raising additional capital.
- The company is experiencing negative cash flows from operations.
- The company's future success depends on the successful commercialization of its products and services.
- The company faces risks related to competing technological and market developments.
- The company may be required to curtail research and development initiatives if it cannot secure additional capital.
- The ongoing war in Ukraine and the conflict in the Middle East could affect the price of materials used in manufacturing.
Future Outlook
Eyenovia expects its research and development and general and administrative expenses to continue to increase and will need to generate significant product revenues to achieve profitability. The company is also planning an interim analysis of the CHAPERONE study data in late 2024 and a meeting with the FDA in late 2024 regarding the collaboration with Senju.
Management Comments
- Management believes that the reacquisition of the MicroPine rights is in the best interest of the company and its shareholders.
- Management is focused on the commercialization of Mydcombi and the development of the Optejet platform.
Industry Context
Eyenovia operates in the ophthalmic pharmaceutical industry, focusing on innovative drug delivery technologies. The reacquisition of MicroPine and the collaboration with Senju are strategic moves to strengthen its pipeline and market position. The company's focus on microdosing and digital health aligns with broader trends in the pharmaceutical industry towards more patient-centric and efficient treatments.
Comparison to Industry Standards
- Eyenovia's increased R&D spending is typical for a company in its stage of development, focusing on clinical trials and product development.
- The company's net losses are not uncommon for biotech companies that are still in the pre-profitability stage.
- The reacquisition of MicroPine is a significant strategic move, similar to other companies that have reacquired assets to control their development and commercialization.
- The collaboration with Senju is a common strategy in the pharmaceutical industry to leverage expertise and resources for product development.
- Eyenovia's focus on microdosing and digital health is a differentiator in the ophthalmic market, potentially offering advantages over traditional eye drops.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Increase in Authorized Shares | The company increased the authorized number of shares of common stock from 90,000,000 to 300,000,000. | 2024-06-12 | This change provides the company with greater flexibility to raise capital through equity offerings. |
Stakeholder Impact
- Shareholders face the risk of further dilution due to potential capital raises.
- Employees may be affected by potential cost-cutting measures if the company cannot secure additional funding.
- Customers may benefit from the commercialization of new products like Mydcombi and the potential development of new treatments.
- Suppliers may be impacted by the company's financial situation and potential changes in spending.
- Creditors face the risk of non-payment if the company is unable to continue as a going concern.
Next Steps
- Eyenovia plans to continue the development of its product pipeline, including MicroPine and MicroLine.
- The company will focus on the commercialization of Mydcombi.
- Eyenovia will conduct an interim analysis of the CHAPERONE study data in late 2024.
- The company will meet with the FDA in late 2024 regarding the collaboration with Senju.
- Eyenovia will continue to explore potential collaborations and licensing opportunities.
Key Dates
| Date | Description |
|---|---|
| 2015-03-08 | Date of exclusive license agreement with Senju Pharmaceutical Co.,Ltd. |
| 2019-02 | FDA accepted Eyenovia's Investigational New Drug (IND) to initiate the CHAPERONE study. |
| 2019-06 | First patient enrolled in the CHAPERONE study. |
| 2019-04 | Eyenovia adopted the Eyenovia 401(k) Plan. |
| 2020-08-10 | Eyenovia entered into a license agreement with Arctic Vision. |
| 2020-10-09 | Eyenovia entered into a license agreement with Bausch + Lomb. |
| 2021-09-14 | Amendment to the Arctic Vision License Agreement. |
| 2022 Q4 | Eyenovia released positive top-line results from VISION-2. |
| 2023-08-03 | First commercial sale of Mydcombi. |
| 2023-08-15 | Eyenovia entered into a license agreement with Formosa Pharmaceuticals Inc. |
| 2024-01-12 | Eyenovia entered into an agreement with Bausch + Lomb to reacquire rights to MicroPine. |
| 2024-01-22 | Eyenovia paid Bausch + Lomb $2.0 million in cash as part of the reacquisition agreement. |
| 2024-02 | FDA approved the use of Eyenovia's primary Mydcombi manufacturing facility. |
| 2024-02-24 | Eyenovia issued a note payable for the purchase of a directors and officers liability insurance policy. |
| 2024-03-04 | FDA approved Formosa's clobetasol propionate ophthalmic suspension 0.05%. |
| 2024-03-14 | Effective date of the acceptance by Eyenovia of the transfer and assignment of the FDA approval from Formosa. |
| 2024-04-08 | Eyenovia entered into a securities purchase agreement for a registered direct offering. |
| 2024-04-11 | Transfer of regulatory documents and study elements from Bausch + Lomb to Eyenovia completed. |
| 2024-04-23 | Eyenovia and Bausch + Lomb executed a letter agreement regarding defective clinical supply. |
| 2024-04-26 | Eyenovia paid Formosa $1.0 million in cash as part of the milestone payment. |
| 2024-04-29 | Eyenovia issued 613,496 shares of common stock to Formosa as part of the milestone payment. |
| 2024-05-03 | Eyenovia issued 2,299,397 shares of common stock to Bausch + Lomb. |
| 2024-06-12 | Eyenovia shareholders approved an increase in authorized number of shares of common stock. |
| 2024-06 | Eyenovia made its initial principal payment related to the loan and security agreement with Avenue. |
| 2024-06-30 | End of the reporting period for the quarterly report. |
| 2024-07-01 | Eyenovia closed on a registered direct offering, raising $5.0 million in gross proceeds. |
| 2024-07-12 to 2024-07-25 | Closing bid price of Eyenovia's common stock was at $1.00 per share or greater. |
| 2024-07-23 | Eyenovia entered into a collaboration agreement with Senju. |
| 2024-07-24 | Eyenovia received written comments from the FDA regarding a clinical bridging study for Mydcombi. |
| 2024-07-26 | Eyenovia received notice from Nasdaq that it had regained compliance with the minimum bid price requirement. |
| 2024-08-01 | Eyenovia had onboarded nine sales representatives. |
| 2024-08-09 | Number of outstanding shares of the registrants common stock was 64,059,440. |
| 2024-08-14 | Date of the filing of the quarterly report. |
Keywords
Eyenovia, MicroPine, Mydcombi, Optejet, ophthalmic, myopia, presbyopia, clinical trials, FDA, licensing, pharmaceutical, commercialization
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.